Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Community Practice Connections™: Saturday Night Tumor Board: Applying the Evidence to Challenging Scenarios in Patients With NSCLC & EGFR Mutations

Release Date: July 31, 2019
Expiration Date: July 31, 2020
Media: Internet - based

Activity Overview

Community Practice Connections™: Saturday Night Tumor Board: Applying the Evidence to Challenging Scenarios in Patients With NSCLC & EGFR Mutations provides case-based discussion of clinical data guiding therapy for patients with non–small cell lung cancer (NSCLC) and mutations in the EGFR gene. Clinical scenarios include first-line therapy, molecular testing, management of disease progression, and treatment of patients with central nervous system (CNS) metastases. Interactive clinical vignettes are followed by short video interviews with leading experts in the management of patients with lung cancer. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by healthcare professionals engaged in the care of patients with EGFR mutation–positive NSCLC.

Benefits of Participating

  • Assess plasma-based and tissue-based molecular testing approaches to optimize selection in the first-line setting and subsequent lines of therapy for patients with advanced NSCLC
  • Evaluate key clinical trials informing treatment of patients with newly diagnosed EGFR mutation–positive NSCLC
  • Discuss clinical data on resistance mechanisms and managing disease progression in patients with EGFR mutation–positive NSCLC
  • Describe therapeutic approaches for patients with EGFR mutation–positive NSCLC and CNS metastases

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, educational content/video files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational program is directed toward primarily medical oncologists. Nurse practitioners, nurses, physician assistants, pharmacists, investigators, and other healthcare professionals interested in the treatment of lung cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Assess the application of liquid-based and tumor-based molecular testing approaches to choose initial and subsequent lines of therapy for patients with advanced, EGFR mutation–positive NSCLC
  • Evaluate clinical data on strategies for the initial management of patients with EGFR mutation–positive NSCLC
  • Discuss clinical data informing the management of acquired resistance and disease progression in patients with EGFR mutation–positive NSCLC
  • Describe management strategies for patients with EGFR mutation–positive NSCLC and brain metastases and/or treatment-related adverse events

Faculty, Staff, and Planners’ Disclosures

Faculty

Mark G. Kris
Mark G. Kris, MD
Attending Physician, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: AstraZeneca, Pfizer, Regeneron; Other: Food & Beverage: Genentech.

Zofia Piotrowska
Zofia Piotrowska, MD
Instructor of Medicine, Harvard Medical School
Massachusetts General Hospital
Boston, MA

Disclosures: Grant Research Support: AstraZeneca, Takeda, Spectrum, Novartis, Tesaro; Consultant: AstraZeneca, Spectrum, Immuno¬Gen, Guardant Health.

Jyoti D. Patel
Jyoti D. Patel, MD, FASCO
Professor of Medicine
University of Chicago
Director of Thoracic Oncology
University of Chicago Comprehensive Cancer Center
Chicago, IL

Disclosures: Consultant: AbbVie, Takeda, AstraZeneca.

Helena A. Yu
Helena A. Yu, MD
Assistant Attending
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: AstraZeneca; Other: Travel Funding: Lilly; Research Funding for Clinical Research to Institution: Lilly, Astra¬Zeneca, Novartis, Daiichi, Pfizer, Astellas.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By